Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IRD

Opus Genetics Inc

Dec 13 • 04:00PM ET

1.02

Dollar change -0.09
Percentage change -8.11	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IWC BSVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	17.68%	Shs Outstand	26.20M	Perf Week	-8.11%
Market Cap	29.59M	Forward P/E	-	EPS next Y	-0.85	Insider Trans	2.01%	Shs Float	25.99M	Perf Month	-5.56%
Income	-27.19M	PEG	-	EPS next Q	-0.06	Inst Own	8.02%	Short Float	3.38%	Perf Quarter	-21.54%
Sales	8.38M	P/S	3.53	EPS this Y	-94.57%	Inst Trans	-	Short Ratio	5.63	Perf Half Y	-38.18%
Book/sh	1.31	P/B	0.78	EPS next Y	5.03%	ROA	-57.50%	Short Interest	0.88M	Perf Year	-62.08%
Cash/sh	1.26	P/C	0.81	EPS next 5Y	-	ROE	-64.30%	52W Range	0.85 - 3.40	Perf YTD	-66.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	53.36%	ROI	-79.28%	52W High	-69.99%	Beta	0.18
Dividend TTM	-	Quick Ratio	6.63	Sales past 5Y	1322.70%	Gross Margin	227.22%	52W Low	19.56%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	6.63	EPS Y/Y TTM	-178.92%	Oper. Margin	-351.68%	RSI (14)	41.42	Volatility	7.95% 7.97%
Employees	14	Debt/Eq	0.00	Sales Y/Y TTM	-85.35%	Profit Margin	-324.45%	Recom	1.00	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-216.00%	Payout	-	Rel Volume	1.28	Prev Close	1.11
Sales Surprise	69.49%	EPS Surprise	-22.11%	Sales Q/Q	-67.60%	Earnings	Nov 12 BMO	Avg Volume	156.26K	Price	1.02
SMA20	-5.79%	SMA50	-12.41%	SMA200	-34.56%	Trades		Volume	200,776	Change	-8.11%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-24	Resumed	H.C. Wainwright	Buy	$8

Dec-03-24 08:00AM	Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 (GlobeNewswire) +5.22%
Nov-14-24 06:40AM	Opus Genetics reinstated with a Buy at H.C. Wainwright (TipRanks)
Nov-12-24 08:00AM	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire)
07:59AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 12:00PM	The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics (PR Newswire)
05:31PM	Loading…
Oct-23-24 05:31PM	Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics (TipRanks) -12.03%
Oct-22-24 04:05PM	Ocuphire Pharma Announces Acquisition of Opus Genetics (GlobeNewswire)
Sep-30-24 08:00AM	Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology (GlobeNewswire)
Sep-05-24 08:43PM	UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
08:00AM	Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
Aug-13-24 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire) -20.85%
Aug-08-24 08:00AM	Ocuphire Pharma to Present at Two Investor Conferences in August (GlobeNewswire) +6.10%
Jul-10-24 08:00AM	Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July (GlobeNewswire) +6.45%
Jun-06-24 07:57AM	Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June (GlobeNewswire)
May-10-24 01:53PM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.24%
08:00AM	Loading…
08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting (GlobeNewswire)
May-03-24 08:00AM	Ocuphire Pharma to Present at the Aegis Virtual Conference (GlobeNewswire) +7.57%
Apr-22-24 08:00AM	Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting (GlobeNewswire) -8.76%
Apr-11-24 10:03AM	First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery (GlobeNewswire)
Apr-01-24 07:14AM	Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris (GlobeNewswire) +10.95%
Mar-15-24 11:53AM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update (GlobeNewswire) -16.39%
Mar-04-24 08:18AM	Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-23-24 08:00AM	Ocuphire Pharma to Present in the BIO CEO & Investor Conference (GlobeNewswire)
Feb-15-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-14-24 08:00AM	Ocuphire Pharma Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Feb-05-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Jan-24-24 04:10PM	Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:41AM	Loading…
Jan-11-24 07:41AM	Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now (Zacks) -7.81%
Jan-04-24 08:00AM	Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions (GlobeNewswire)
Nov-30-23 08:00AM	Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII (GlobeNewswire) +11.31%
Nov-27-23 04:38PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer (GlobeNewswire)
Nov-13-23 08:00AM	Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Nov-02-23 08:00AM	Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy (GlobeNewswire)
Nov-01-23 04:52PM	Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:05AM	Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director (GlobeNewswire)
Oct-26-23 08:00AM	Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase (GlobeNewswire)
Oct-06-23 08:00AM	Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October (GlobeNewswire)
Sep-27-23 08:00AM	Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (PR Newswire) -5.97%
08:00AM	Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (GlobeNewswire)
Sep-11-23 09:41AM	Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences (GlobeNewswire)
Sep-07-23 09:00AM	Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September (GlobeNewswire)
Aug-28-23 08:00AM	Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium (GlobeNewswire)
Aug-11-23 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August (GlobeNewswire)
Jul-26-23 08:00AM	Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit (GlobeNewswire)
Jul-10-23 05:19PM	Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-23 08:00AM	Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Associations Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference (GlobeNewswire)
Jun-12-23 08:00AM	Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023 (GlobeNewswire)
May-24-23 04:05PM	Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.20%
May-15-23 08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update (GlobeNewswire) -16.75%
May-02-23 08:30AM	Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator (GlobeNewswire) -8.31%
Apr-25-23 08:00AM	Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs (GlobeNewswire) -7.66%
Apr-21-23 08:00AM	Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer (GlobeNewswire) -16.07%
Mar-30-23 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update (GlobeNewswire) +6.39%
Mar-23-23 08:00AM	Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting (GlobeNewswire)
Feb-16-23 08:30AM	Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings (GlobeNewswire)
Feb-13-23 08:00AM	Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis (GlobeNewswire) +14.94%
Jan-25-23 04:01PM	Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA (GlobeNewswire) -19.95%
Jan-09-23 07:00AM	Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia (GlobeNewswire) +7.26%
Dec-06-22 06:00AM	Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis (GlobeNewswire) -5.28%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-21-22 08:00AM	Ocuphire to Present at Five Upcoming Investor/Industry Conferences (GlobeNewswire)
Nov-07-22 04:05PM	Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances (GlobeNewswire) -5.02% +19.71%
Nov-04-22 04:30PM	Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:10AM	Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA) (GlobeNewswire) -6.03%
Oct-24-22 08:56AM	Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting (GlobeNewswire)
Oct-07-22 07:00AM	Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference (GlobeNewswire)
Oct-06-22 09:27AM	Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease (GlobeNewswire)
Sep-29-22 08:00AM	Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team (GlobeNewswire)
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE)
Sep-15-22 07:00AM	Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting (GlobeNewswire)
Sep-12-22 08:00AM	Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA (GlobeNewswire)
Sep-08-22 08:00AM	Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy (GlobeNewswire)
Sep-06-22 09:00AM	Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-12-22 07:00AM	Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update (GlobeNewswire) -8.96%
Aug-08-22 01:16PM	We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate (Simply Wall St.)
07:00AM	Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August (GlobeNewswire)
Aug-03-22 08:00AM	Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance (GlobeNewswire)
Jul-07-22 08:00AM	Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July (GlobeNewswire)
Jun-29-22 09:00AM	Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication (GlobeNewswire)
Jun-24-22 08:59AM	BlackBerry Earnings Reveal Smaller Than Expected Loss (Barrons.com) -5.94%
Jun-08-22 08:00AM	Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting (GlobeNewswire)
May-19-22 07:00AM	Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances (GlobeNewswire)
May-13-22 08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update (GlobeNewswire) +8.04%
May-11-22 08:00AM	Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Apr-28-22 07:00AM	Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis (GlobeNewswire)
Apr-26-22 09:00AM	Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022 (GlobeNewswire) -6.27%
Apr-19-22 08:00AM	Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyecelerator (GlobeNewswire)
Apr-06-22 08:00AM	Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA (GlobeNewswire)
Mar-29-22 07:00AM	Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis (GlobeNewswire) -16.24%
Mar-24-22 08:00AM	Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update (GlobeNewswire) +5.57%
Mar-16-22 07:30AM	Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy (GlobeNewswire)
Mar-10-22 09:27AM	Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference (GlobeNewswire)
Mar-08-22 08:00AM	Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis (GlobeNewswire)
Feb-08-22 08:00AM	Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations (GlobeNewswire) +8.11%

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
YERXA BENJAMIN R	President	Nov 21 '24	Buy	0.98	10,000	9,834	342,800	Nov 25 04:18 PM
Magrath George	Chief Executive Officer	Nov 15 '24	Buy	1.01	90,294	91,215	483,244	Nov 19 04:08 PM
Magrath George	Chief Executive Officer	Nov 18 '24	Buy	1.02	9,706	9,943	492,950	Nov 19 04:08 PM
Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	May 22 '24	Buy	1.76	3,500	6,178	78,500	May 24 04:07 PM
Magrath George	Chief Executive Officer	May 17 '24	Buy	1.75	5,000	8,772	430,000	May 21 04:18 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Mar 21 '24	Buy	2.05	2,000	4,100	2,000	Mar 25 04:44 PM
Jhaveri Nirav S.	Chief Financial Officer	Mar 21 '24	Buy	2.10	10,000	21,000	150,000	Mar 25 04:40 PM
Magrath George	Chief Executive Officer	Mar 18 '24	Buy	1.96	25,000	49,050	425,000	Mar 20 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRD

Opus Genetics Inc

Upgrade your FINVIZ experience